BUSINESS● LOW1h ago · Sep 9, 2026, 4:53 PM
Ocugen slips after interim trial data for Stargardt disease candidate
Seeking Alpha Tech · north america
Ocugen's stock declined following the release of interim trial data for its Stargardt disease candidate. This indicates a market reaction to the experimental treatment's progress.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS22m ago10-year Treasury auction brings afternoon relief to bond marketSeeking Alpha TechBUSINESS23m ago« A stock market introduction for the people »: the Dangote refinery hopes to attract millions of small investorsJeune AfriqueBUSINESS26m agoSailPoint outlines FY2029 targets including at least $2.1B ARR amid agentic AI pushSeeking Alpha TechBUSINESS27m agoFedEx unveils new digital tools to simplify international shippingSeeking Alpha Tech